VCYT: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Total revenue	376,509	-
Laboratory supplies and reagents expense	43,134	-
Sample collection expense	9,398	-
Compensation expense	17,906	-
Other cost	14,017	-
Allocation of facilities and it expenses	9,989	-
Cost of revenue-Testing	94,444	-
Product costs	1,864	-
License fees and royalties	888	-
Other cost	2,980	-
Allocation of facilities and it expenses	454	-
Cost of revenue-Product	6,186	-
Compensation expense	3,318	-
Other cost	3,118	-
Allocation of facilities and it expenses	925	-
Cost of revenue-Biopharmaceutical And Other	7,361	-
Intangible asset amortization - cost of revenue	7,959	-
Gross profit	260,559	-
Compensation expense	27,840	-
Direct expense	10,946	-
Other research and development expenses	5,278	-
Allocation of facilities and it expenses	5,901	-
Total research and development	49,965	-
Compensation expense	52,214	-
Direct expense	3,564	-
Other selling and marketing expenses	10,880	-
Allocation of facilities and it expenses	7,567	-
Total selling and marketing	74,225	-
Compensation expense	62,121	-
Other general and administrative expenses	56,132	-
Allocation of facilities and it expenses	-24,836	-
Total general and administrative	93,417	-
Impairment of assets	20,505	-
Intangible asset amortization - operating expenses-Intangible Asset Amortization	1,865	-
Other income, net	6,985	-
Income tax (benefit) provision	2,363	-
Net income	25,204	6,067
Depreciation and amortization	16,117	10,851
Loss on disposal of property, plant and equipment	-15	-15
Stock-based compensation	32,700	21,943
Deferred income taxes	-13	74
Noncash lease expense	2,289	1,600
Revaluation of acquisition-related contingent consideration	-2,713	-2,879
Effect of foreign currency on operations	3,845	5,050
Amortization of discount on short-term investments	2,619	-
Impairment loss	20,505	20,505
Non-cash loss on deconsolidation of subsidiary	-3,863	-
Accounts receivable	3,858	4,283
Supplies and inventory	2,642	2,863
Prepaid expenses and other current assets	6,416	5,460
Other assets	-331	1,389
Operating lease liabilities	-1,681	-1,186
Accounts payable	-547	3,113
Accrued liabilities and deferred revenue	7,034	-2,091
Net cash provided by operating activities	83,724	38,967
Acquisition of c2i, net of cash acquired	0	0
Purchase of short-term investments	99,998	99,998
Proceeds from maturity of short-term investments	102,116	51,061
Purchases of property, plant and equipment	5,897	3,105
Net cash used in investing activities	-3,779	-52,042
Payment of taxes on vested restricted stock units	14,645	11,831
Proceeds from the exercise of common stock options and employee stock purchases	10,572	4,781
Net cash (used in) provided by financing activities	-4,073	-7,050
Increase in cash, cash equivalents and restricted cash	75,872	-20,125
Effect of foreign currency on cash, cash equivalents and restricted cash	707	647
Net increase in cash, cash equivalents and restricted cash	76,579	-19,478
Cash and cash equivalents at beginning of period	240,631	-
Cash and cash equivalents at end of period	317,210	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

VCYT: the cashflow